- Home
- ENTA vs FLL Comparison
ENTA vs FLL Comparison
Compare ENTA & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- FLL
- Stock Information
- Founded
- ENTA 1995
- FLL 1987
- Country
- ENTA United States
- FLL United States
- Employees
- ENTA N/A
- FLL N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- ENTA Health Care
- FLL Consumer Discretionary
- Exchange
- ENTA Nasdaq
- FLL Nasdaq
- Market Cap
- ENTA 154.0M
- FLL 166.6M
- IPO Year
- ENTA 2013
- FLL 1993
- Fundamental
- Price
- ENTA $5.59
- FLL $4.18
- Analyst Decision
- ENTA Buy
- FLL Strong Buy
- Analyst Count
- ENTA 4
- FLL 4
- Target Price
- ENTA $17.25
- FLL $6.25
- AVG Volume (30 Days)
- ENTA 228.9K
- FLL 149.5K
- Earning Date
- ENTA 05-05-2025
- FLL 03-06-2025
- Dividend Yield
- ENTA N/A
- FLL N/A
- EPS Growth
- ENTA N/A
- FLL N/A
- EPS
- ENTA N/A
- FLL N/A
- Revenue
- ENTA $66,590,999.00
- FLL $292,065,000.00
- Revenue This Year
- ENTA N/A
- FLL $13.51
- Revenue Next Year
- ENTA N/A
- FLL $8.46
- P/E Ratio
- ENTA N/A
- FLL N/A
- Revenue Growth
- ENTA N/A
- FLL 21.16
- 52 Week Low
- ENTA $4.71
- FLL $3.77
- 52 Week High
- ENTA $17.80
- FLL $5.90
- Technical
- Relative Strength Index (RSI)
- ENTA 31.66
- FLL 41.56
- Support Level
- ENTA $5.65
- FLL $4.11
- Resistance Level
- ENTA $5.96
- FLL $4.53
- Average True Range (ATR)
- ENTA 0.36
- FLL 0.18
- MACD
- ENTA -0.15
- FLL 0.03
- Stochastic Oscillator
- ENTA 4.77
- FLL 39.66
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.